- Categories:About Us
- Time of issue:2019-05-24 00:00:00
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. Currently, the company is developing a diversified portfolio of over 10 novel pipeline products. IASO’s leading asset, CT103A, an innovative anti-BCMA CAR T- cell therapy under pivotal study for relapsed/refractory multiple myeloma (R/R MM), was granted Breakthrough Therapeutic Designation (BPD) by China’s National Medical Products Administration (NMPA) in February 2021.